CZ386392A3 - Alpha interferon - Google Patents

Alpha interferon Download PDF

Info

Publication number
CZ386392A3
CZ386392A3 CS923863A CS386392A CZ386392A3 CZ 386392 A3 CZ386392 A3 CZ 386392A3 CS 923863 A CS923863 A CS 923863A CS 386392 A CS386392 A CS 386392A CZ 386392 A3 CZ386392 A3 CZ 386392A3
Authority
CZ
Czechia
Prior art keywords
ifn
alpha2
plasmid
alpha2c
peak
Prior art date
Application number
CS923863A
Other languages
Czech (cs)
English (en)
Inventor
Gunther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/de
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CZ386392A3 publication Critical patent/CZ386392A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CS923863A 1990-07-10 1992-12-23 Alpha interferon CZ386392A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (de) 1990-07-10 1990-07-10 Glykosyliertes ifnalpha
DE19904035877 DE4035877A1 (de) 1990-11-12 1990-11-12 O-glycosyliertes ifn-alfa2

Publications (1)

Publication Number Publication Date
CZ386392A3 true CZ386392A3 (en) 1993-08-11

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
CS923863A CZ386392A3 (en) 1990-07-10 1992-12-23 Alpha interferon

Country Status (16)

Country Link
EP (1) EP0538300B1 (enExample)
JP (1) JPH06502987A (enExample)
KR (1) KR930701601A (enExample)
AT (1) ATE104348T1 (enExample)
AU (1) AU650893B2 (enExample)
CA (1) CA2084514A1 (enExample)
CZ (1) CZ386392A3 (enExample)
DE (1) DE59101397D1 (enExample)
DK (1) DK0538300T3 (enExample)
ES (1) ES2063515T3 (enExample)
FI (1) FI930058A7 (enExample)
HU (1) HUT65846A (enExample)
NO (1) NO930059D0 (enExample)
PL (1) PL297610A1 (enExample)
SK (1) SK386392A3 (enExample)
WO (1) WO1992001055A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
CA2202148A1 (en) 1994-10-28 1996-05-09 Belinda Giesendorf Polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
RU2610173C1 (ru) * 2016-03-30 2017-02-08 Илья Александрович Марков Рекомбинантная плазмида pFM-IFN-17, обеспечивающая экспрессию интерферона альфа-2b человека, рекомбинантная плазмида pFM-АР, обеспечивающая экспрессию фермента метионинаминопептидазы E. coli, биплазмидный штамм Escherichia coli FM-IFN-АР (pFM-IFN-17, pFM-АР) - продуцент (Met-) рекомбинантного интерферона альфа-2b человека

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
EP0085693A1 (en) * 1981-08-14 1983-08-17 A/S Alfred Benzon Subjects relating to human inteferon-alpha subtype proteins and corresponding antibodies
DE3306060A1 (de) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps

Also Published As

Publication number Publication date
SK386392A3 (en) 1994-08-10
NO930059L (no) 1993-01-08
JPH06502987A (ja) 1994-04-07
WO1992001055A1 (de) 1992-01-23
NO930059D0 (no) 1993-01-08
FI930058A0 (fi) 1993-01-08
KR930701601A (ko) 1993-06-12
AU8208291A (en) 1992-02-04
FI930058L (fi) 1993-01-08
EP0538300B1 (de) 1994-04-13
ES2063515T3 (es) 1995-01-01
DK0538300T3 (da) 1994-10-10
HUT65846A (en) 1994-07-28
CA2084514A1 (en) 1992-01-11
EP0538300A1 (de) 1993-04-28
ATE104348T1 (de) 1994-04-15
HU9300036D0 (en) 1993-04-28
AU650893B2 (en) 1994-07-07
FI930058A7 (fi) 1993-01-08
PL297610A1 (enExample) 1992-07-13
DE59101397D1 (de) 1994-05-19

Similar Documents

Publication Publication Date Title
SK386392A3 (en) Interferon alpha
JP5980467B2 (ja) Ｉｌ−７薬物原料、組成物、製造及び使用
JP3946638B2 (ja) 生体内エリスロポエチン活性が増強された融合蛋白質
KR100545720B1 (ko) 당화된 면역글로불린 및 이를 포함하는 면역접합체
UA73719C2 (en) Human interleukin-2 mutant which activates preferably t-cells as compared with natural killer cells, pharmaceutical composition, polynucleotide, vector, procariotic cell, a method for the stimulation of immune system
CZ288890B6 (cs) MGDF polypeptid pro stimulaci růstu a diferenciaci megakaryocytů
JP3860097B2 (ja) エリスロポエチン生体内活性強化融合蛋白質
RO117110B1 (ro) POLIPEPTIDA LIGAND mpl, ACID NUCLEIC, CARE O CODIFICA, VECTOR DE EXPRESIE, PROCEDEU PENTRU PRODUCEREA POLIPEPTIDEI LIGAND, SI COMPOZITIE FARMACEUTICA CU ACEASTA
EA012802B1 (ru) Гликозилированный il-7, получение и применение
CN102648286A (zh) 在巴斯德毕赤氏酵母中生产缺乏与针对宿主细胞抗原的抗体的可检测交叉结合活性的蛋白质的方法
EP0790305B1 (en) Mutant human growth hormones and their uses
CA2209298C (en) Mpl ligand analogs
WO1993000357A1 (en) Therapeutic polypeptides based on von willebrand factor
JP2001515719A (ja) Ｍｐｌリガンド類似体
KR100237582B1 (ko) Tpo 활성을 갖는 단백질의 제조방법
KR100407087B1 (ko) 사람혈관성ibp-유사성장인자
JP4042923B2 (ja) 免疫関連因子
WO2002060947A2 (en) Glycoforms a fas ligand inhibitory protein analog
WO2001000664A2 (en) Secreted alpha-helical protein-36
HK1075465B (en) Il-7 drug substance, il-7 comprising composition, preparation and uses thereof
WO2000078804A1 (fr) Proteines regulatrices de la reponse immunitaire
JP2003500054A (ja) 分泌型アルファヘリックスタンパク質−３２